Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Antimicrobial resistance

Malaria resistant to both artemisinin and piperaquine identified in Cambodia

Malaria that is resistant to both drugs contained in the combination dihydroartemisinin–piperaquine has been identified in Cambodia for the first time. In the image, anopheles stephensi mosquito, a vector for malaria

Source: Jim Gathany / Centers for Disease Control and Prevention’s Public Health Image Library

The anopheles stephensi mosquito (pictured) is a vector for malaria

Malaria that is resistant to both drugs contained in the combination dihydroartemisinin–piperaquine has been identified in patients in Cambodia for the first time, according to a study published in The Lancet Infectious Diseases[1]. Resistance to artemisinin is already well-documented but this is the first time parasites resistant to piperaquine have also been established in patients.

A research collaboration between the United States, Cambodia and the UK recruited 241 patients aged between 2 and 65 years with uncomplicated acute malaria. Patients were recruited from three different areas in Cambodia where artemisinin resistance ranged from 76%, 21% and 4%. They were given standard three-day treatment with dihydroartemisinin–piperaquine. After 63 days, 46%, 16% and 2% of the patients had recrudescence — the recurrence of malaria after a long latency period, often the result of treatment failure. Samples of recrudescent Plasmodium falciparum malaria parasites had higher piperaquine minimum inhibitory concentrations and a higher frequency of kelch13 mutations, associated with artemisinin resistance.

The new evidence, in combination with previous studies, suggest that “parasites resistant to artemisinin and piperaquine are spreading rapidly in Cambodia”, say the authors of the study, who add that “investigations of alternative treatment approaches are urgently needed”.

A combination treatment of piperaquine and artemisinin is recommended as the first-line treatment for multi-drug resistant malaria around the world. Combination treatment makes the development of resistance less likely. However, there has been a rapid spread of artemisinin resistance, making it easier for an already artemisinin-resistant parasite to also develop resistance to piperaquine.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20200436

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Malaria that is resistant to both drugs contained in the combination dihydroartemisinin–piperaquine has been identified in Cambodia for the first time. In the image, anopheles stephensi mosquito, a vector for malaria

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.